Mediastinal Tumor Size and Response to Chemotherapy Are the only Prognostic Factors in Supradiaphragmatic Hodgkin's Disease Treated by ABVD Plus Radiotherapy: Ten-Year Results of the Paris-Ouest-France 81/12 Trial, Including 262 Patients

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1928-1935

  Colonna, Pierre ^b   Jais, Jean Philippe ^b   Desablens, Bernard ^b   Harousseau, Jean Luc ^b   Brière, Jean ^b   Boasson, Marc ^b   Lemevel, Annick ^b   Casassus, Philippe ^b   Le Prisé, Pierre Yves ^b   Guilhot, François ^b   Ghandour, Christiane ^b   Lejeune, Françoise ^b   Andrieu, Jean Marie ^a  

^a Hopital Laennec   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; METHYLPREDNISOLONE; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; FRANCE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM TUMOR; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MEDIASTINAL NEOPLASMS; METHYLPREDNISOLONE; MIDDLE AGED; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SURVIVAL RATE; VINBLASTINE;

EID: 0029889969     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1928     Document Type: Article

References (30)

1. Glatstein E: Radiotherapy in Hodgkin's disease. Past achievements and future progress. Cancer 39:837-842, 1977
2. Tubiana M, Mathé G, Hayat M, et al: Le traitement des stades cliniques I et II de la maladie de Hodgkin. Nouv Rev Fr Hematol 18:463-472, 1977
3. DeVita VT, Simon RM, Hubbard SM, et al: Curability of advanced Hodgkin's disease with CT. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587-595, 1980
4. Andrieu JM, Dana M, Desprez-Curely JP, et al: MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to IIIB. Long-term results of the prospective trial H72 (1972-1976, 334 patients). Hematol Oncol 3:219-231, 1985
5. Andrieu JM, Coscas Y, Cramer P, et al: Chemotherapy plus radiotherapy in clinical stages IA to IIIB Hodgkin's disease. Result of the H77 trial (1977-1980), in Cavalli F, Bonadonna G, Rozenweig M (eds): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Boston, MA, Nijhoff, 1985, pp 351-353
6. Viviani S, Santoro A, Ragni G, et al: Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Int J Cancer Clin Oncol 27:601-605, 1985
7. Boivin JF, Hutchinson GB, Zauber AG, et al: Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87:732-741, 1995
8. Valagussa P, Santoro A, Fossati Bellani F, et al: Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Proc Am Assoc Cancer Res 22:197, 1981 (abstr 782)
9. Desablens B, Tourani JM, Casassus Ph, et al: Traitement des formes localisées de la maladie de Hodgkin par 3 cures de chimiothérapie (ABVD-MP) associées à une radiothérapie focale élargie et lombo-splénique prophylactique. Protocole POF 81/12. Presse Med 18:1917-1921, 1989
10. Ifrah N, Hunault M, Jais JP, et al: Infradiapnragmatic Hodgkin disease. Long term results of combined modality therapy. Leuk Lymph 18:179-184, 1995
11. Carbone PP, Kaplan HS, Mushoff K, et al: Report of the Committee on Hodgkin's Disease. Staging classification. Cancer Res 38:288-305, 1976
12. Tourani JM, Lévy R, Colonna P, et al: High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol 10:1086-1094, 1992
13. Peto R, Picke MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
14. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, pp 122-127
15. Kaplan HS: Hodgkin's Disease (ed 2). Cambridge. MA, Harvard University, 1980, pp 370-372
16. Urba WJ, Longo DL: Hodgkin's disease. N Engl J Med 326:678-687, 1992
17. Straus DJ: Modern treatment approaches for Hodgkin's disease. Curr Opin Oncol 5:785-790, 1993
18. Anderson H, Deakin DP, Wagstaff J, et al: A randomized study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: A report from the Manchester Lymphoma Group. Br J Cancer 49:695-702, 1984
19. Hoppe RT, Horning SJ, Rosenberg SA: The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease. Cancer Surv 4:459-475, 1985
20. Andrieu JM, Ifrah N, Payen C, et al: Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8:1148-1154, 1990
21. Colonna P, Andrieu JM, Ghouadni R, et al: Hodgkin's disease, clinical stages IA to IIIB: Combined modality therapy (3 MOPP followed by curative and prophylactic radiotherapy including the spleen). Six-year results. Eur J Haematol 39:356-361, 1987
22. Santoro A, Bonadonna G, Valagussa P, et al: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27-37, 1987
23. da Cunha MF, Meistrich ML, Fuller LM, et al: Recovery of spermatogenesis after treatment for Hodgkin's disease: Limiting dose of MOPP chemotherapy. J Clin Oncol 2:571-577, 1984
24. Bonadonna G: Modern treatment of malignant lymphomas: A multidisciplinary approach? Ann Oncol 5:S5-S16, 1994 (suppl 2)
25. Joss RA, Bacchi M, Buser K, et al: Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Ann Oncol 5:253-258, 1994
26. Behar R, Hoppe RT: Radiation therapy in the management of bulky mediastinal Hodgkin's disease. Cancer 66:75-79, 1990
27. Mauch P, Tarbell H, Weinstein H, et al: Stage IA and IIA supradiaphragmatic Hodgkin's disease. Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6:1576-1583, 1988
28. Straus DJ, Gaynor JJ, Myers J, et al: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non cross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8:1173-1186, 1990
29. Gisselbrecht C, Ferme C: Prognostic factors in advanced Hodgkin's disease: problems and pitfalls. Towards an international prognostic index. Leuk Lymph 15:23-24, 1995 (suppl 1)
30. Kuentz M, Reyes F, Brun B, et al: Early response to chemotherapy as prognostic factor in Hodgkin's disease. Cancer 52:780-785, 1983